Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $208.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) offering positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE